CTMX Financials
CytomX Therapeutics Inc - Financial statements & key metrics
Stock Price
$5.37
Market Cap
$913.26M
P/E Ratio
18.0
EPS
$0.30
Income Statement Highlights
Most Recent Quarter: 2024-12-31
Revenue
$138.10M
Gross Profit
$138.10M
Operating Income
$25.00M
Net Income
$31.87M
EPS (Diluted)
$-
Balance Sheet Highlights
Total Assets
$120.53M
Total Liabilities
$120.99M
Shareholders Equity
$-456000.00
Cash & Equivalents
$38.05M
Total Debt
-
Cash Flow Highlights
Operating Cash Flow
$-86.23M
CapEx
$310000
Free Cash Flow
$-86.54M
Profitability Metrics
Gross Margin
100.0%
Operating Margin
-2.6%
Net Margin
0.2%
ROE
0.7%
View Complete Financial Statements
Full income statements, balance sheets, and cash flows for multiple periods
Open Full FinancialsFrequently Asked Questions
What is CTMX revenue?
CTMX's most recent quarterly revenue was $138.10M. Annual revenue can be calculated by summing the four most recent quarters.
Is CTMX profitable?
CTMX reported a profit of $31.87M in the most recent quarter. The net profit margin is 0.2%.
What is CTMX market cap?
CTMX has a market capitalization of $913.26M, making it a small-cap stock.
Does CTMX have debt?
View CTMX's balance sheet for debt information.
What is CTMX cash flow?
CTMX's most recent quarterly free cash flow was $-86.54M.